The American Society of Clinical Oncology’s (ASCO) recently published antiemetic guideline update excluded oncology pharmacists from the targeted audience. A letter to the Editor was submitted to the Journal of Clinical Oncology by the Canadian Association of Pharmacy Oncology (CAPhO), in collaboration with HOPA and ISOPP, to bring awareness to the omission.
Paul Hesketh, who replied on behalf of ASCO, agreed and confirmed that subsequent publications will “include oncology pharmacists and other key oncology professionals for whom the guideline applies.”
This is a positive step forward. Thank you CAPhO for submitting the letter. Read the full story on the CAPhO website.